D-Day approaching for Cell Therapeutics' pixantrone


On 10 February 2010, members of the FDA's Oncologic Drugs Advisory Committee will meet to hear testimony and debate whether or not to approve Cell Therapeutics' application to market pixantrone, the company's experimental drug to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

For Cell Therapeutics, it's fairly safe to say that the fate of the company relies on pixantrone's approval, which while not a sure thing, is nonetheless very likely. The drug has been proven to be fairly effective in tumor reduction and it seems to have a low cardiac toxicity profile. It has not been shown to extend patients' lives; fortunately for Cell Therapeutics, and perhaps not so fortunately for future patients, FDA approval doesn't hinge on this all-important factor.

By Ross Bonander

More on pixantrone from Cell Therapeutics.

LymphomaInfo Social